Global Cancer Immunotherapy Market, Market Forecast, Market Trend, Market Research and Opportunity, Market Study, Size and Share – 2014-2027


Global Cancer Immunotherapy Market is expected to grow with a CAGR of 14.7% from 2017 to 2027

Immunotherapy harnesses parts of the immune system to fight cancer. It works by boosting the immune system generally, or by training the immune system to specifically target cancer cells. There are three types of immunotherapy currently in use.

The key factors that drive the development of global cancer immunotherapy market incorporate ascent in incidence and prevalence of cancer, technological advancement in treatment therapies, increment in number of R&D for the treatment of cancer, and specificity and viability of cancer immunotherapy for the treatment of extensive variety of cancers, for example, breast Cancer, melanoma cancer, head & neck cancer, colorectal cancer, lung c cancer, prostate cancer, others (Gastric, Renal Cell Carcinoma, Cervical and Lymphoma). Furthermore, the ascent in human healthcare expenditure and healthcare insurance are required to fuel the market development during the forecast period 2017-2027. However, lack of awareness and shortage of experienced and skilled professionals limit the development of global immunotherapy market.

The global cancer immunotherapy market has been segmented on the basis of technology, application, and region. On the basis of technology, the global immunotherapy market is segmented into monoclonal antibodies, Cytokines, and immunomodulators, and others. The monoclonal antibodies segment is expected to account for the largest share of the global market in 2016; also the monoclonal antibodies segment is expected to grow at the highest CAGR during the forecast period 2017-2027.

Based on application, the global cancer immunotherapy market is segmented into breast Cancer, melanoma cancer, head & neck cancer, colorectal cancer, lung cancer, prostate cancer, others (Gastric, Renal Cell Carcinoma, Cervical and Lymphoma). The lung cancer segment is expected to witness the highest CAGR from 2017 to 2027, owing to the increase incidence of this type of cancer

North America held the biggest revenue share in 2016. Rising rate of the cancer, expanding ease of access to modern therapeutics, combined with extending geriatric population, is impelling the market in the area. Then again, factors, for example, challenges in clinical trials, combined with higher expenses and quickly changing reimbursement policies, are hindering development of the global immunotherapy market in North America.

Asia Pacific is anticipated to encounter the fastest development and growing with the highest CAGR. Rising prevalence of the cancer and in turn, rising death rate is impelling interest for immunotherapy in the area. In addition, presence of market players with significant investment in the market, for example, AstraZeneca; Merck and Co., Inc.; and Pfizer, Inc., is boosting the Asia Pacific market.

New and advanced immunotherapy drugs are being introduced in China and Japan. These nations have a few progressing clinical trials and in addition approvals for new drugs molecules and combination therapies. Approvals of new treatment drugs in China and Japan are boosting the immunotherapy for treatment of cancer.

The major players in this market include F. Hoffman La-Roche Ltd. (Switzerland), Merck (U.S.), Advaxis inc, Bristol-Myers Squibb (U.S.), Bayer AG (Germany), Novartis (Switzerland),   AstraZeneca (U.K.), Pfizer (U.S.), and Immunomedics inc


Market Dynamics


  • Rise in incidence & prevalence of cancer
  • Technological advancements in treatment therapies
  • Increase in number of R&D for the treatment of cancer


  • Lack of awareness in public.
  • Shortage of experienced healthcare professionals.

Report Key Benefits


Market Segments

By Technology

  • Monoclonal Antibodies
  • Cytokines & Immunomodulators
  • Others

By Application

  • Breast Cancer
  • Melanoma
  • Head & Neck Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Prostate Cancer
  • Others (Gastric, Renal Cell Carcinoma, Cervical and Lymphoma)

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Brazil
    • Argentina
    • South Africa
    • Middle East
    • Rest of LAMEA

 Company Profiles

  • Hoffmann-La Roche AG
  • Merck & Co., Inc
  • Advaxis Inc
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Novartis AG
  • Astrazeneca plc.
  • Pfizer Inc.
  • Immunomedics Inc

Target Audience

  • Service providers, dealers, distributors, and suppliers in Cancer Immunotherapy..
  • Healthcare institutes
  • Research institutes, associations and academicians
  • Market research and consulting firms
Place an Order


Looking for a Market Analysis Report?